ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer has agreed to pay $1.3 billion to Sanofi-Aventis for full rights to the experimental inhaled diabetes drug Exubera. The deal includes an insulin-manufacturing plant in Frankfurt, Germany, that previously was jointly owned by the companies. Pfizer had originally partnered with Aventis in the development of Exubera. Later, however, Pfizer claimed that Sanofi-Synthélabo's acquisition of Aventis in 2004 triggered a "change-in-control" clause, and this claim led to speculation that Pfizer was interested in acquiring full control of the drug. "This deal has been widely anticipated since late last summer," Morgan Stanley analyst Jami Rubin wrote to clients in a research note. The analyst added that, although the price seemed high because of some of the uncertainties still surrounding the commercial potential of Exubera, it did not seem unreasonable. An FDA advisory committee recommended approving Exubera in September 2005, but a month later the agency extended by three months the deadline for its review of the drug. The agency is expected to make a final decision on whether to approve Exubera by the end of this month.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter